在规划条件下乌克兰耐药结核病BPaL(M)方案的有效性

IF 8.2 1区医学 Q1 IMMUNOLOGY

Clinical Infectious Diseases Pub Date : 2025-04-26 DOI:10.1093/cid/ciaf214

Victor Naestholt Dahl, Ole Skouvig Pedersen, Tetiana Butova, Mykhailo Kuzhko, Olena Raznatovska, Andrii Fedorec, Vitalii Vekshyn, Valentyna Hlynenko, Nataliia Yevsiukova, Leonid Hryshchuk, Svitlana Kornaha, Nataliia Chursina, Natalia Kondratyuk, Lyubov Markovtsiy, Vasyl Skryp, Artemii Bogomolov, Tetiana Klymenko, Daria Yankovska, Mykola Ostrovskyy, Iryna Makoida, Daria Levandovska, Yuulia Shpak, Vitalii Didyk, Olha Siomak, Dmytro Butov

{"title":"在规划条件下乌克兰耐药结核病BPaL(M)方案的有效性","authors":"Victor Naestholt Dahl, Ole Skouvig Pedersen, Tetiana Butova, Mykhailo Kuzhko, Olena Raznatovska, Andrii Fedorec, Vitalii Vekshyn, Valentyna Hlynenko, Nataliia Yevsiukova, Leonid Hryshchuk, Svitlana Kornaha, Nataliia Chursina, Natalia Kondratyuk, Lyubov Markovtsiy, Vasyl Skryp, Artemii Bogomolov, Tetiana Klymenko, Daria Yankovska, Mykola Ostrovskyy, Iryna Makoida, Daria Levandovska, Yuulia Shpak, Vitalii Didyk, Olha Siomak, Dmytro Butov","doi":"10.1093/cid/ciaf214","DOIUrl":null,"url":null,"abstract":"Bedaquiline, pretomanid, and linezolid, with or without moxifloxacin, have revolutionized treatment for drug-resistant tuberculosis. In Ukraine, we observed an 86% (n=394/460) success rate under programmatic conditions when drugs were accessible, exceeding prior estimates (58%) and aligning with trials (80–90%). However, access and implementation remain a concern in conflict-affected settings.","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":"3 1","pages":""},"PeriodicalIF":8.2000,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effectiveness of the BPaL(M) Regimen for Drug-Resistant Tuberculosis in Ukraine under Programmatic Conditions\",\"authors\":\"Victor Naestholt Dahl, Ole Skouvig Pedersen, Tetiana Butova, Mykhailo Kuzhko, Olena Raznatovska, Andrii Fedorec, Vitalii Vekshyn, Valentyna Hlynenko, Nataliia Yevsiukova, Leonid Hryshchuk, Svitlana Kornaha, Nataliia Chursina, Natalia Kondratyuk, Lyubov Markovtsiy, Vasyl Skryp, Artemii Bogomolov, Tetiana Klymenko, Daria Yankovska, Mykola Ostrovskyy, Iryna Makoida, Daria Levandovska, Yuulia Shpak, Vitalii Didyk, Olha Siomak, Dmytro Butov\",\"doi\":\"10.1093/cid/ciaf214\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Bedaquiline, pretomanid, and linezolid, with or without moxifloxacin, have revolutionized treatment for drug-resistant tuberculosis. In Ukraine, we observed an 86% (n=394/460) success rate under programmatic conditions when drugs were accessible, exceeding prior estimates (58%) and aligning with trials (80–90%). However, access and implementation remain a concern in conflict-affected settings.\",\"PeriodicalId\":10463,\"journal\":{\"name\":\"Clinical Infectious Diseases\",\"volume\":\"3 1\",\"pages\":\"\"},\"PeriodicalIF\":8.2000,\"publicationDate\":\"2025-04-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/cid/ciaf214\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/cid/ciaf214","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

贝达喹啉、普雷托马奈和利奈唑胺，无论是否使用莫西沙星，都彻底改变了耐药结核病的治疗。在乌克兰，我们观察到，当药物可获得时，在规划条件下的成功率为86% (n=394/460)，超过了先前的估计（58%），并与试验（80-90%）一致。然而，在受冲突影响的环境中，获取和执行仍然是一个令人关切的问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Effectiveness of the BPaL(M) Regimen for Drug-Resistant Tuberculosis in Ukraine under Programmatic Conditions

Bedaquiline, pretomanid, and linezolid, with or without moxifloxacin, have revolutionized treatment for drug-resistant tuberculosis. In Ukraine, we observed an 86% (n=394/460) success rate under programmatic conditions when drugs were accessible, exceeding prior estimates (58%) and aligning with trials (80–90%). However, access and implementation remain a concern in conflict-affected settings.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Infectious Diseases 医学-传染病学

CiteScore

25.00

自引率

2.50%

发文量

900

审稿时长

3 months

期刊介绍： Clinical Infectious Diseases (CID) is dedicated to publishing original research, reviews, guidelines, and perspectives with the potential to reshape clinical practice, providing clinicians with valuable insights for patient care. CID comprehensively addresses the clinical presentation, diagnosis, treatment, and prevention of a wide spectrum of infectious diseases. The journal places a high priority on the assessment of current and innovative treatments, microbiology, immunology, and policies, ensuring relevance to patient care in its commitment to advancing the field of infectious diseases.